Status:

UNKNOWN

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study

Lead Sponsor:

Jaeb Center for Health Research

Collaborating Sponsors:

Juvenile Diabetes Research Foundation

University of Minnesota

Conditions:

Type1 Diabetes

Eligibility:

All Genders

7-17 years

Brief Summary

The purpose of this extension study is to continue to follow the participants who completed the CLVer RCT for up to 3 additional years. The goal for Cohort A is to evaluate the longer-term effects of ...

Detailed Description

Participants who complete the CLVer RCT will be eligible to enroll in the CLVer Extension Study. Informed consent and assent, when applicable, will be obtained. Participants will be contacted every 3 ...

Eligibility Criteria

Inclusion

  • Completed CLVer RCT 12 month visit and willing to join observational extension.

Exclusion

    Key Trial Info

    Start Date :

    May 7 2021

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    December 18 2025

    Estimated Enrollment :

    77 Patients enrolled

    Trial Details

    Trial ID

    NCT06177691

    Start Date

    May 7 2021

    End Date

    December 18 2025

    Last Update

    December 20 2023

    Active Locations (6)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (6 locations)

    1

    Stanford University

    Palo Alto, California, United States, 94304

    2

    Barbara Davis Center

    Aurora, Colorado, United States, 80045

    3

    Yale University

    New Haven, Connecticut, United States, 06511

    4

    Indiana University

    Indianapolis, Indiana, United States, 46202